Table 2. Immunosuppressive therapy at the time of anal cancer diagnosis.
| Immunosuppressive therapy (n) | Total (n=18) | SCC (n=6) | HSIL (n=9) | LSIL (n=2) | Small cell carcinoma (n=1) |
|---|---|---|---|---|---|
| Immunomodulators (azathioprine/6-MP/methotrexate) | 4 | 1 | 2 | 1 | 0 |
| Biological therapy | 2 | 0 | 2 | 0 | 0 |
| Immunomodulators and anti-TNF (combination) | 1 | 0 | 1 | 0 | 0 |
| Steroids | 2 | 0 | 2 | 0 | 0 |
| Cyclosporine/tacrolimus | 2 | 0 | 1 | 1 | 0 |
| Mycophenolate | 1 | 0 | 0 | 1 | 0 |
| None | 5 | 2 | 3 | 0 | 0 |
| Unknown | 8 | 3 | 3 | 1 | 1 |
HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; SCC, squamous cell carcinoma; TNF, tumor necrosis factor.